Cargando…
Hepatitis B virus infection in an HBsAb-positive lymphoma patient who received chemotherapy: A case report
RATIONALE: Tumor chemotherapy could weaken the immune system of patients, which might enhance the body sensitivities to the exogenous pathogens, among which the hepatitis B virus (HBV) infection should be concerned because of the higher chances of infection and the severe outcomes, especially in Eas...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682831/ https://www.ncbi.nlm.nih.gov/pubmed/29095312 http://dx.doi.org/10.1097/MD.0000000000008518 |
_version_ | 1783278182479167488 |
---|---|
author | Kang, Fu-Biao Wang, Ling Sun, Dian-Xing |
author_facet | Kang, Fu-Biao Wang, Ling Sun, Dian-Xing |
author_sort | Kang, Fu-Biao |
collection | PubMed |
description | RATIONALE: Tumor chemotherapy could weaken the immune system of patients, which might enhance the body sensitivities to the exogenous pathogens, among which the hepatitis B virus (HBV) infection should be concerned because of the higher chances of infection and the severe outcomes, especially in East Asia. The titer level of hepatitis B surface antibody (HBsAb) higher than 10 IU/L is considered to offer immunocompetent individuals adequate protection. However, whether this level is enough to the tumor patients during chemotherapy remains unclear. PATIENT CONCERNS: A 58-year-old female lymphoma patient was admitted to our hospital for asthenia, nausea, vomiting, and abnormal liver function lasting over 1 week and diagnosed as acute hepatitis B. The patient just finished a course of chemotherapy with CHOP regimen and had recent record (78.61 IU/L) of HBsAb positive. The only risk of infection we could found was that the patient had received blood transfusion shortly after chemotherapy from a donor who was recovering from an asymptomatic acute HBV infection. INTERVENTION: The patient was administered with entecavir and glycyrrhizic acid agent, and then the disease was resolved successfully with hepatitis B surface antigen serological conversion. LESSONS: Tumor chemotherapy might have weakened the immune system of the patient and enhanced the body sensitivities to hepatitis B virus, then led to the infection. We concluded that HBsAb-positive status, at least “weakly positive,” might not enough to provide protection for tumor patients on chemotherapy though this level was enough for health individuals and donors recuperating from subclinical acute hepatitis B might be another potential risk of HBV infection. |
format | Online Article Text |
id | pubmed-5682831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-56828312017-11-28 Hepatitis B virus infection in an HBsAb-positive lymphoma patient who received chemotherapy: A case report Kang, Fu-Biao Wang, Ling Sun, Dian-Xing Medicine (Baltimore) 4900 RATIONALE: Tumor chemotherapy could weaken the immune system of patients, which might enhance the body sensitivities to the exogenous pathogens, among which the hepatitis B virus (HBV) infection should be concerned because of the higher chances of infection and the severe outcomes, especially in East Asia. The titer level of hepatitis B surface antibody (HBsAb) higher than 10 IU/L is considered to offer immunocompetent individuals adequate protection. However, whether this level is enough to the tumor patients during chemotherapy remains unclear. PATIENT CONCERNS: A 58-year-old female lymphoma patient was admitted to our hospital for asthenia, nausea, vomiting, and abnormal liver function lasting over 1 week and diagnosed as acute hepatitis B. The patient just finished a course of chemotherapy with CHOP regimen and had recent record (78.61 IU/L) of HBsAb positive. The only risk of infection we could found was that the patient had received blood transfusion shortly after chemotherapy from a donor who was recovering from an asymptomatic acute HBV infection. INTERVENTION: The patient was administered with entecavir and glycyrrhizic acid agent, and then the disease was resolved successfully with hepatitis B surface antigen serological conversion. LESSONS: Tumor chemotherapy might have weakened the immune system of the patient and enhanced the body sensitivities to hepatitis B virus, then led to the infection. We concluded that HBsAb-positive status, at least “weakly positive,” might not enough to provide protection for tumor patients on chemotherapy though this level was enough for health individuals and donors recuperating from subclinical acute hepatitis B might be another potential risk of HBV infection. Wolters Kluwer Health 2017-11-03 /pmc/articles/PMC5682831/ /pubmed/29095312 http://dx.doi.org/10.1097/MD.0000000000008518 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0 |
spellingShingle | 4900 Kang, Fu-Biao Wang, Ling Sun, Dian-Xing Hepatitis B virus infection in an HBsAb-positive lymphoma patient who received chemotherapy: A case report |
title | Hepatitis B virus infection in an HBsAb-positive lymphoma patient who received chemotherapy: A case report |
title_full | Hepatitis B virus infection in an HBsAb-positive lymphoma patient who received chemotherapy: A case report |
title_fullStr | Hepatitis B virus infection in an HBsAb-positive lymphoma patient who received chemotherapy: A case report |
title_full_unstemmed | Hepatitis B virus infection in an HBsAb-positive lymphoma patient who received chemotherapy: A case report |
title_short | Hepatitis B virus infection in an HBsAb-positive lymphoma patient who received chemotherapy: A case report |
title_sort | hepatitis b virus infection in an hbsab-positive lymphoma patient who received chemotherapy: a case report |
topic | 4900 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682831/ https://www.ncbi.nlm.nih.gov/pubmed/29095312 http://dx.doi.org/10.1097/MD.0000000000008518 |
work_keys_str_mv | AT kangfubiao hepatitisbvirusinfectioninanhbsabpositivelymphomapatientwhoreceivedchemotherapyacasereport AT wangling hepatitisbvirusinfectioninanhbsabpositivelymphomapatientwhoreceivedchemotherapyacasereport AT sundianxing hepatitisbvirusinfectioninanhbsabpositivelymphomapatientwhoreceivedchemotherapyacasereport |